FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220783090> ?p ?o ?g. }

• W4220783090 endingPage "105806" @default.
• W4220783090 startingPage "105806" @default.
• W4220783090 abstract "Ribavirin inhibits eukaryotic translation initiation factor 4E (eIF4E), thereby decreasing cap-dependent translation. In this two-part study, we assessed the pharmacodynamic effects and therapeutic potential of ribavirin in human papillomavirus (HPV)-related malignancies.In the pharmacodynamic study, ribavirin (400 mg BID for 14 days) was evaluated in 8 patients with HPV-positive localized oropharyngeal carcinoma with phosphorylated-eIF4E (p-eIF4E) ≥ 30%. In the therapeutic study, ribavirin (1400 mg BID in 28-day cycles, continuously dosed) was evaluated in 12 patients with recurrent and/or metastatic HPV-related cancer. Dose interruptions or reductions were allowed according to prespecified criteria. Toxicities were assessed in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events version 4; response was assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Patients remained on study until disease progression or unacceptable toxicity.Six patients were evaluable in the pharmacodynamic study: 4 had decreased p-eIF4E after 14 days of ribavirin. In the therapeutic study, 12 patients were evaluable for toxicity, and 9 were evaluable for response. Among these, median follow-up was 3.5 months, and best overall response was stable disease in 5 patients and progression of disease in 4 patients. Median progression-free survival was 1.8 months. The most common treatment-related adverse events (grade > 2) were anemia, dyspnea, and hyperbilirubinemia. All patients had anemia (grades 1-3), with 33% having at least 1 dose reduction.Oral ribavirin decreases p-eIF4E levels and is well-tolerated. However, a clear signal of efficacy in patients with recurrent and/or metastatic HPV-related cancers was not observed. (NCT02308241, NCT01268579)." @default.
• W4220783090 created "2022-04-03" @default.
• W4220783090 creator A5003273432 @default.
• W4220783090 creator A5005775817 @default.
• W4220783090 creator A5024957945 @default.
• W4220783090 creator A5036572642 @default.
• W4220783090 creator A5072271778 @default.
• W4220783090 creator A5078178893 @default.
• W4220783090 creator A5090434123 @default.
• W4220783090 date "2022-05-01" @default.
• W4220783090 modified "2023-10-18" @default.
• W4220783090 title "Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus–related malignancies" @default.
• W4220783090 cites W1857980043 @default.
• W4220783090 cites W1964675052 @default.
• W4220783090 cites W1965163574 @default.
• W4220783090 cites W1968622004 @default.
• W4220783090 cites W1969206572 @default.
• W4220783090 cites W1975106131 @default.
• W4220783090 cites W1980234430 @default.
• W4220783090 cites W1987495826 @default.
• W4220783090 cites W1992477322 @default.
• W4220783090 cites W1996235422 @default.
• W4220783090 cites W2001788009 @default.
• W4220783090 cites W2005234434 @default.
• W4220783090 cites W2007765039 @default.
• W4220783090 cites W2008410413 @default.
• W4220783090 cites W2013802037 @default.
• W4220783090 cites W2015792313 @default.
• W4220783090 cites W2027545702 @default.
• W4220783090 cites W2028332244 @default.
• W4220783090 cites W2033489247 @default.
• W4220783090 cites W2034654277 @default.
• W4220783090 cites W2039955907 @default.
• W4220783090 cites W2063176348 @default.
• W4220783090 cites W2065825082 @default.
• W4220783090 cites W2073362868 @default.
• W4220783090 cites W2082778443 @default.
• W4220783090 cites W2084276349 @default.
• W4220783090 cites W2086394668 @default.
• W4220783090 cites W2108564369 @default.
• W4220783090 cites W2111770564 @default.
• W4220783090 cites W2112519486 @default.
• W4220783090 cites W2112845420 @default.
• W4220783090 cites W2113587478 @default.
• W4220783090 cites W2132519593 @default.
• W4220783090 cites W2138216581 @default.
• W4220783090 cites W2149546612 @default.
• W4220783090 cites W2153949330 @default.
• W4220783090 cites W2163239105 @default.
• W4220783090 cites W2168805216 @default.
• W4220783090 cites W2307170928 @default.
• W4220783090 cites W2461456620 @default.
• W4220783090 cites W2589584077 @default.
• W4220783090 cites W2757843953 @default.
• W4220783090 cites W2766016099 @default.
• W4220783090 cites W2793442391 @default.
• W4220783090 cites W2898336689 @default.
• W4220783090 cites W2925815206 @default.
• W4220783090 cites W2936768572 @default.
• W4220783090 cites W2986633517 @default.
• W4220783090 cites W3095158223 @default.
• W4220783090 cites W3096511412 @default.
• W4220783090 doi "https://doi.org/10.1016/j.oraloncology.2022.105806" @default.
• W4220783090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35339025" @default.
• W4220783090 hasPublicationYear "2022" @default.
• W4220783090 type Work @default.
• W4220783090 citedByCount "4" @default.
• W4220783090 countsByYear W42207830902022 @default.
• W4220783090 countsByYear W42207830902023 @default.
• W4220783090 crossrefType "journal-article" @default.
• W4220783090 hasAuthorship W4220783090A5003273432 @default.
• W4220783090 hasAuthorship W4220783090A5005775817 @default.
• W4220783090 hasAuthorship W4220783090A5024957945 @default.
• W4220783090 hasAuthorship W4220783090A5036572642 @default.
• W4220783090 hasAuthorship W4220783090A5072271778 @default.
• W4220783090 hasAuthorship W4220783090A5078178893 @default.
• W4220783090 hasAuthorship W4220783090A5090434123 @default.
• W4220783090 hasBestOaLocation W42207830901 @default.
• W4220783090 hasConcept C111113717 @default.
• W4220783090 hasConcept C112705442 @default.
• W4220783090 hasConcept C121608353 @default.
• W4220783090 hasConcept C126322002 @default.
• W4220783090 hasConcept C143998085 @default.
• W4220783090 hasConcept C197934379 @default.
• W4220783090 hasConcept C203014093 @default.
• W4220783090 hasConcept C2522874641 @default.
• W4220783090 hasConcept C2776408679 @default.
• W4220783090 hasConcept C2777793932 @default.
• W4220783090 hasConcept C2778248108 @default.
• W4220783090 hasConcept C2780040827 @default.
• W4220783090 hasConcept C29730261 @default.
• W4220783090 hasConcept C71924100 @default.
• W4220783090 hasConcept C90924648 @default.
• W4220783090 hasConceptScore W4220783090C111113717 @default.
• W4220783090 hasConceptScore W4220783090C112705442 @default.
• W4220783090 hasConceptScore W4220783090C121608353 @default.
• W4220783090 hasConceptScore W4220783090C126322002 @default.
• W4220783090 hasConceptScore W4220783090C143998085 @default.

• next